Celon Pharma S.A. (WSE:CLN)

Celon Pharma Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	23.37	26.85	32.36	82.9	147.8	43.98
Short-Term Investments	29.16	48.24	82.18	81.72	79.76	-
Cash & Short-Term Investments	52.52	75.09	114.54	164.62	227.55	43.98
Cash Growth	-52.60%	-34.45%	-30.42%	-27.65%	417.42%	-34.06%
Accounts Receivable	45.62	39.26	32.79	27.11	24.67	32.53
Other Receivables	13.81	12.72	15.45	6.59	2.57	9.49
Receivables	59.43	51.99	48.24	33.7	27.25	42.02
Inventory	30.52	30.17	26.41	38.39	23.38	29.76
Other Current Assets	4	3.18	0.56	0.87	0.53	3.48
Total Current Assets	146.47	160.43	189.75	237.58	278.7	119.24
Property, Plant & Equipment	305.48	311.66	333.8	341.59	316.57	313.8
Long-Term Investments	27.68	32.56	11.26	13.25	38.12	12.87
Other Intangible Assets	5.98	8.15	14.29	21.15	27.81	38.38
Long-Term Deferred Tax Assets	17.09	21.55	19.05	28.14	31.94	27.17
Long-Term Deferred Charges	-	-	0.68	0.68	1.36	2.72
Other Long-Term Assets	18.5	9.46	0.47	0.38	12.64	17.7
Total Assets	521.2	543.8	569.31	642.76	707.14	531.89
Accounts Payable	17.94	15.43	10.51	17.47	11.87	18.42
Accrued Expenses	10.37	8.1	7.39	6.8	3.11	6.77
Short-Term Debt	4.74	1.53	12.75	-	-	12.84
Current Portion of Leases	7.56	7.14	7.13	19.43	6.56	3.49
Current Unearned Revenue	14.73	17.92	31.09	56.42	55.83	45.78
Other Current Liabilities	16.79	16.78	17.48	16.32	8.99	26.86
Total Current Liabilities	72.13	66.9	86.34	116.44	86.36	114.15
Long-Term Leases	7.5	8.26	5.71	7.39	8.35	9.16
Long-Term Unearned Revenue	21.9	20.22	22.88	25.62	29.85	39.67
Long-Term Deferred Tax Liabilities	0.15	2.85	3.01	1.32	6.04	-
Other Long-Term Liabilities	-	0.36	5.81	12.35	22.53	24.38
Total Liabilities	101.67	98.59	123.75	163.12	153.14	187.36
Common Stock	5.39	5.39	5.11	5.1	5.1	4.5
Additional Paid-In Capital	551.25	551.25	543.23	587.1	613.51	393.12
Retained Earnings	-140.05	-114.96	-108.64	-119.79	-91.67	-58.57
Comprehensive Income & Other	2.94	3.53	5.85	7.23	27.07	5.48
Shareholders' Equity	419.53	445.21	445.56	479.65	554	344.53
Total Liabilities & Equity	521.2	543.8	569.31	642.76	707.14	531.89
Total Debt	19.79	16.93	25.59	26.82	14.92	25.48
Net Cash (Debt)	32.73	58.16	88.95	137.8	212.63	18.5
Net Cash Growth	-61.95%	-34.62%	-35.45%	-35.19%	1049.56%	-71.56%
Net Cash Per Share	0.62	1.11	1.74	2.70	4.55	0.41
Filing Date Shares Outstanding	53.86	53.86	51.06	51.04	51	45
Total Common Shares Outstanding	53.86	53.86	51.06	51.04	51	45
Working Capital	74.34	93.53	103.41	121.14	192.34	5.1
Book Value Per Share	7.79	8.27	8.73	9.40	10.86	7.66
Tangible Book Value	413.55	437.06	431.26	458.5	526.19	306.16
Tangible Book Value Per Share	7.68	8.12	8.45	8.98	10.32	6.80
Land	6.35	6.35	6.35	6.35	6.35	6.35
Buildings	157.97	157.97	146.4	146.35	146.08	173.5
Machinery	319.77	317.71	272.86	190.43	177.34	164.34
Construction In Progress	16.9	15.75	79.95	74.3	50.63	31.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.